Hansa Biopharma: increase in number of shares and votes

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST. This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through...

LUND, Sweden, 28/06/2024 (informazione.it - comunicati stampa - salute e benessere)

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
[email protected]

Stephanie Kenney, VP Global Corporate Affairs
[email protected]

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.